Comments on: 23andMe: Will the personal-genomics company need Big Pharma to make money? http://venturebeat.com/2007/11/19/23andme-will-the-personal-genomics-company-need-big-pharma-to-make-money/ News About Tech, Money and Innovation Thu, 26 Nov 2009 01:33:32 +0000 http://wordpress.org/?v=2.8.5 hourly 1 By: VentureBeat » deCODEme’s underwhelming personal-genomics service http://venturebeat.com/2007/11/19/23andme-will-the-personal-genomics-company-need-big-pharma-to-make-money/comment-page-1/#comment-748960 VentureBeat » deCODEme’s underwhelming personal-genomics service Wed, 23 Jan 2008 22:12:21 +0000 http://venturebeat.com/2007/11/19/23andme-does-the-personal-genomics-company-require-big-pharma-to-make-money/#comment-748960 [...] of press attention since they launched last November (not least of all from us — see here and here for starters). Unless you happened to have a spare $1,000 laying around, however, you were pretty [...] [...] of press attention since they launched last November (not least of all from us — see here and here for starters). Unless you happened to have a spare $1,000 laying around, however, you were pretty [...]

]]> By: VentureBeat » The nitty-gritty on Knome: How it works http://venturebeat.com/2007/11/19/23andme-will-the-personal-genomics-company-need-big-pharma-to-make-money/comment-page-1/#comment-658562 VentureBeat » The nitty-gritty on Knome: How it works Fri, 30 Nov 2007 16:28:39 +0000 http://venturebeat.com/2007/11/19/23andme-does-the-personal-genomics-company-require-big-pharma-to-make-money/#comment-658562 [...] Knome, of course, has some ideas, but will let its customers decide if they want to participate in, say, research studies on genetic influences in disease, response to drugs, behavior, intelligence, or anything else. “We certainly hope our clients will want to participate, but our system puts them in control of who has access to their information,” Conde says. At other companies — 23andMe in particular — participation in research studies is effectively required, although customers have some ability to withhold personal, non-genetic information if they choose. Such research studies, particularly those involving the pharma and biotech industries, may in fact emerge as a primary money-making opportunity for companies like 23andMe — see, for instance, our coverage here. [...] [...] Knome, of course, has some ideas, but will let its customers decide if they want to participate in, say, research studies on genetic influences in disease, response to drugs, behavior, intelligence, or anything else. “We certainly hope our clients will want to participate, but our system puts them in control of who has access to their information,” Conde says. At other companies — 23andMe in particular — participation in research studies is effectively required, although customers have some ability to withhold personal, non-genetic information if they choose. Such research studies, particularly those involving the pharma and biotech industries, may in fact emerge as a primary money-making opportunity for companies like 23andMe — see, for instance, our coverage here. [...]

]]> By: VentureBeat » The nitty-gritty on Knome: How it works http://venturebeat.com/2007/11/19/23andme-will-the-personal-genomics-company-need-big-pharma-to-make-money/comment-page-1/#comment-658576 VentureBeat » The nitty-gritty on Knome: How it works Fri, 30 Nov 2007 16:28:39 +0000 http://venturebeat.com/2007/11/19/23andme-does-the-personal-genomics-company-require-big-pharma-to-make-money/#comment-658576 [...] Knome, of course, has some ideas, but will let its customers decide if they want to participate in, say, research studies on genetic influences in disease, response to drugs, behavior, intelligence, or anything else. “We certainly hope our clients will want to participate, but our system puts them in control of who has access to their information,” Conde says. At other companies — 23andMe in particular — participation in research studies is effectively required, although customers have some ability to withhold personal, non-genetic information if they choose. Such research studies, particularly those involving the pharma and biotech industries, may in fact emerge as a primary money-making opportunity for companies like 23andMe — see, for instance, our coverage here. [...] [...] Knome, of course, has some ideas, but will let its customers decide if they want to participate in, say, research studies on genetic influences in disease, response to drugs, behavior, intelligence, or anything else. “We certainly hope our clients will want to participate, but our system puts them in control of who has access to their information,” Conde says. At other companies — 23andMe in particular — participation in research studies is effectively required, although customers have some ability to withhold personal, non-genetic information if they choose. Such research studies, particularly those involving the pharma and biotech industries, may in fact emerge as a primary money-making opportunity for companies like 23andMe — see, for instance, our coverage here. [...]

]]> By: VentureBeat » The nitty-gritty on Knome: How it works http://venturebeat.com/2007/11/19/23andme-will-the-personal-genomics-company-need-big-pharma-to-make-money/comment-page-1/#comment-658590 VentureBeat » The nitty-gritty on Knome: How it works Fri, 30 Nov 2007 16:28:39 +0000 http://venturebeat.com/2007/11/19/23andme-does-the-personal-genomics-company-require-big-pharma-to-make-money/#comment-658590 [...] Knome, of course, has some ideas, but will let its customers decide if they want to participate in, say, research studies on genetic influences in disease, response to drugs, behavior, intelligence, or anything else. “We certainly hope our clients will want to participate, but our system puts them in control of who has access to their information,” Conde says. At other companies — 23andMe in particular — participation in research studies is effectively required, although customers have some ability to withhold personal, non-genetic information if they choose. Such research studies, particularly those involving the pharma and biotech industries, may in fact emerge as a primary money-making opportunity for companies like 23andMe — see, for instance, our coverage here. [...] [...] Knome, of course, has some ideas, but will let its customers decide if they want to participate in, say, research studies on genetic influences in disease, response to drugs, behavior, intelligence, or anything else. “We certainly hope our clients will want to participate, but our system puts them in control of who has access to their information,” Conde says. At other companies — 23andMe in particular — participation in research studies is effectively required, although customers have some ability to withhold personal, non-genetic information if they choose. Such research studies, particularly those involving the pharma and biotech industries, may in fact emerge as a primary money-making opportunity for companies like 23andMe — see, for instance, our coverage here. [...]

]]> By: VentureBeat » Genomics for the rich: Knome reads your entire genetic code — for the low, low price of $350,000 http://venturebeat.com/2007/11/19/23andme-will-the-personal-genomics-company-need-big-pharma-to-make-money/comment-page-1/#comment-657190 VentureBeat » Genomics for the rich: Knome reads your entire genetic code — for the low, low price of $350,000 Thu, 29 Nov 2007 20:04:04 +0000 http://venturebeat.com/2007/11/19/23andme-does-the-personal-genomics-company-require-big-pharma-to-make-money/#comment-657190 [...] extensively covered personal-genomics startups such as 23andMe and Navigenics, which along with DeCode Genetics’ DecodeMe are offering individuals a first [...] [...] extensively covered personal-genomics startups such as 23andMe and Navigenics, which along with DeCode Genetics’ DecodeMe are offering individuals a first [...]

]]> By: VentureBeat » Genomics for the rich: Knome will read your entire genetic code, for the low, low price of $350,000 http://venturebeat.com/2007/11/19/23andme-will-the-personal-genomics-company-need-big-pharma-to-make-money/comment-page-1/#comment-656966 VentureBeat » Genomics for the rich: Knome will read your entire genetic code, for the low, low price of $350,000 Thu, 29 Nov 2007 18:16:20 +0000 http://venturebeat.com/2007/11/19/23andme-does-the-personal-genomics-company-require-big-pharma-to-make-money/#comment-656966 [...] extensively covered personal-genomics startups such as 23andMe and Navigenics, which along with DeCode Genetics’ DecodeMe are offering individuals a broad [...] [...] extensively covered personal-genomics startups such as 23andMe and Navigenics, which along with DeCode Genetics’ DecodeMe are offering individuals a broad [...]

]]> By: Bud http://venturebeat.com/2007/11/19/23andme-will-the-personal-genomics-company-need-big-pharma-to-make-money/comment-page-1/#comment-650302 Bud Mon, 26 Nov 2007 21:06:29 +0000 http://venturebeat.com/2007/11/19/23andme-does-the-personal-genomics-company-require-big-pharma-to-make-money/#comment-650302 Well thought out arguement. One thing I liked about DeCodeMe's offer/service is that they let you download a copy of your genome scan. I didn't see that capability on 23AndMe's site. ALSO, I wonder if either company will let you deleate your account and your genome scan from their system? Otherwise, it does seem like a bit of a scam. You pay them 1K to scan your genome (granted, they give you some good info in return) and then they make the big money by selling it back to Pharmaceutical companies... Well thought out arguement. One thing I liked about DeCodeMe’s offer/service is that they let you download a copy of your genome scan. I didn’t see that capability on 23AndMe’s site. ALSO, I wonder if either company will let you deleate your account and your genome scan from their system? Otherwise, it does seem like a bit of a scam. You pay them 1K to scan your genome (granted, they give you some good info in return) and then they make the big money by selling it back to Pharmaceutical companies…

]]> By: Personalized Genetics: Decode Me or not Decode Me? « ScienceRoll http://venturebeat.com/2007/11/19/23andme-will-the-personal-genomics-company-need-big-pharma-to-make-money/comment-page-1/#comment-648454 Personalized Genetics: Decode Me or not Decode Me? « ScienceRoll Sun, 25 Nov 2007 23:05:26 +0000 http://venturebeat.com/2007/11/19/23andme-does-the-personal-genomics-company-require-big-pharma-to-make-money/#comment-648454 [...] 23andMe: Will the personal-genomics company need Big Pharma to make money? (VentureBeat): Still, neither academics nor disease-focused foundations are likely to provide the level of funding that could turn a company like 23andMe from an intriguing curiosity into a commercial powerhouse. Who does have that kind of moolah? Big Pharma and Big Biotech, of course. Recall, for instance, that 23andMe is backed not only by Google, but also by Genentech. [...] [...] 23andMe: Will the personal-genomics company need Big Pharma to make money? (VentureBeat): Still, neither academics nor disease-focused foundations are likely to provide the level of funding that could turn a company like 23andMe from an intriguing curiosity into a commercial powerhouse. Who does have that kind of moolah? Big Pharma and Big Biotech, of course. Recall, for instance, that 23andMe is backed not only by Google, but also by Genentech. [...]

]]> By: piotr http://venturebeat.com/2007/11/19/23andme-will-the-personal-genomics-company-need-big-pharma-to-make-money/comment-page-1/#comment-645024 piotr Wed, 21 Nov 2007 20:31:55 +0000 http://venturebeat.com/2007/11/19/23andme-does-the-personal-genomics-company-require-big-pharma-to-make-money/#comment-645024 This is the most insightful coverage of 23andMe I have seen. I might only add that the aggregate data they will sell to drug companies is much better than the data sold to consumer. According to the <a href="https://www.23andme.com/you/faqwin/dataaccuracy/" rel="nofollow">info on their site</a>, the reproducibility of the Illumina chip is 99.9%, and of the custom chip 99.6%. Thus, in any single run, 550 + 120 SNPs are expected to be wrong. Since at the moment we are looking only at a handful of markers, it is not impossible to imagine an extremely unlucky consumer who gets ALL his disease-related SNPs messed up! On the other hand, once you start pooling thousands of customers and apply appropriate statistics, the data becomes rock solid. I am very excited about the possibilites offered by personal genomics, but this post reminded me of the argument Michael Crichton makes in his book "Next" for rescinding the Bayh-Dole Act: Currently, taxpayers finance research at the universities, and than pay top dollar for a drug they help finance. And the flood of life-saving therapies never happened. This is the most insightful coverage of 23andMe I have seen. I might only add that the aggregate data they will sell to drug companies is much better than the data sold to consumer. According to the info on their site, the reproducibility of the Illumina chip is 99.9%, and of the custom chip 99.6%. Thus, in any single run, 550 + 120 SNPs are expected to be wrong. Since at the moment we are looking only at a handful of markers, it is not impossible to imagine an extremely unlucky consumer who gets ALL his disease-related SNPs messed up! On the other hand, once you start pooling thousands of customers and apply appropriate statistics, the data becomes rock solid.

I am very excited about the possibilites offered by personal genomics, but this post reminded me of the argument Michael Crichton makes in his book “Next” for rescinding the Bayh-Dole Act: Currently, taxpayers finance research at the universities, and than pay top dollar for a drug they help finance. And the flood of life-saving therapies never happened.

]]> By: VentureBeat » 23andMe lets you search and share your genome — today http://venturebeat.com/2007/11/19/23andme-will-the-personal-genomics-company-need-big-pharma-to-make-money/comment-page-1/#comment-643078 VentureBeat » 23andMe lets you search and share your genome — today Tue, 20 Nov 2007 19:06:25 +0000 http://venturebeat.com/2007/11/19/23andme-does-the-personal-genomics-company-require-big-pharma-to-make-money/#comment-643078 [...] REDUX: I take a closer look at 23andMe’s likely business model in this subsequent post. For more stories on VentureBeat Life Sciences, click here.Tagged co:23andme, co:DeCode Genetics, [...] [...] REDUX: I take a closer look at 23andMe’s likely business model in this subsequent post. For more stories on VentureBeat Life Sciences, click here.Tagged co:23andme, co:DeCode Genetics, [...]

]]> By: VentureBeat » 23andMe lets you search and share your genome — today http://venturebeat.com/2007/11/19/23andme-will-the-personal-genomics-company-need-big-pharma-to-make-money/comment-page-1/#comment-643064 VentureBeat » 23andMe lets you search and share your genome — today Tue, 20 Nov 2007 19:06:25 +0000 http://venturebeat.com/2007/11/19/23andme-does-the-personal-genomics-company-require-big-pharma-to-make-money/#comment-643064 [...] REDUX: I take a closer look at 23andMe’s likely business model in this subsequent post. For more stories on VentureBeat Life Sciences, click here.Tagged co:23andme, co:DeCode Genetics, [...] [...] REDUX: I take a closer look at 23andMe’s likely business model in this subsequent post. For more stories on VentureBeat Life Sciences, click here.Tagged co:23andme, co:DeCode Genetics, [...]

]]> By: Mr. Gunn http://venturebeat.com/2007/11/19/23andme-will-the-personal-genomics-company-need-big-pharma-to-make-money/comment-page-1/#comment-642728 Mr. Gunn Tue, 20 Nov 2007 15:56:06 +0000 http://venturebeat.com/2007/11/19/23andme-does-the-personal-genomics-company-require-big-pharma-to-make-money/#comment-642728 Well, Google likes anything that generates massive amounts of data, that much we know. The first thing I thought of was that this would enable pharma to market those orphan drugs they've all got waiting in the wings, because people would know if they were in the group of responders. Well, Google likes anything that generates massive amounts of data, that much we know.

The first thing I thought of was that this would enable pharma to market those orphan drugs they’ve all got waiting in the wings, because people would know if they were in the group of responders.

]]> By: DNA Network Members Discuss Personal Genomics Service Providers 23andMe, deCODEme, and Navigenics http://venturebeat.com/2007/11/19/23andme-will-the-personal-genomics-company-need-big-pharma-to-make-money/comment-page-1/#comment-642658 DNA Network Members Discuss Personal Genomics Service Providers 23andMe, deCODEme, and Navigenics Tue, 20 Nov 2007 14:45:43 +0000 http://venturebeat.com/2007/11/19/23andme-does-the-personal-genomics-company-require-big-pharma-to-make-money/#comment-642658 [...] David Hamilton at VentureBeat Life Sciences - 23andMe: Will the personal-genomics company need Big Pharma to make money? [...] [...] David Hamilton at VentureBeat Life Sciences – 23andMe: Will the personal-genomics company need Big Pharma to make money? [...]

]]> By: Will 23andMe sell your personal (really personal) information? « HIPPOCRATech http://venturebeat.com/2007/11/19/23andme-will-the-personal-genomics-company-need-big-pharma-to-make-money/comment-page-1/#comment-642560 Will 23andMe sell your personal (really personal) information? « HIPPOCRATech Tue, 20 Nov 2007 11:50:48 +0000 http://venturebeat.com/2007/11/19/23andme-does-the-personal-genomics-company-require-big-pharma-to-make-money/#comment-642560 [...] Linda Avery and Anne Wojcicki emphasized the education pursuit into the genomic properties.  Others have suggested that 23andMe will sell a customer’s information to pharmaceutical and biotech [...] [...] Linda Avery and Anne Wojcicki emphasized the education pursuit into the genomic properties.  Others have suggested that 23andMe will sell a customer’s information to pharmaceutical and biotech [...]

]]>